Vernakalant ((3R,1'R,2'R)-Isomer) HCl
Vernakalant hydrochloride, also known as RSD1235, is a novel, relatively atrial-selective antiarrhythmic drug which can terminate acute atrial fibrillation (AF) in humans at 2 to 5 mg/kg. It belongs mixed ion channel blocker. It may be more atrial-selective than available agents in treatment of antiarrhythmic. It blocks atrial potassium channels, thereby prolonging repolarization. It also blocks atrial sodium channels. It also slightly blocks the hERG potassium channel, leading to a prolonged QT interval, which may theoretically increase the risk of ventricular tachycardia, though this does not seem to be clinically relevant. It is more effective at high heart rates. It was initially developed by Cardiome Pharma, and the intravenous formulation was bought for further development by Merck in April 2009. In September 2012, Merck terminated its agreements with Cardiome and has consequently returned all rights of the drug back to Cardiome. The drug (under brand name Brinavess) was approved in Europe on 1 September 2010. An oral formulation underwent Phase II clinical trials between 2005 and 2008.
Supplier | BOC Sciences |
---|---|
Product # | 748810-28-8 |
Pricing | Inquire |
Cas | 748810-28-8 |
Molecular Weight | 385.93 |
Molecular Formula | C20H32NO4Cl |
Canonical SMILES | COC1=C(C=C(C=C1)CCOC2CCCCC2N3CCC(C3)O)OC.Cl |